Shuoshi Bio controlling shareholder seeks board election, excluding current chairman
The control dispute at Chinese diagnostics firm Shuoshi Bio (688399) escalated after its controlling shareholder, Shaoxing Runkang Bio-Medical Investment Partnership, requested an extraordinary shareholder meeting to elect a new board. The proposed slate of eight candidates excludes current Chairman Wang Guoqiang and Director Liang Kecheng but includes former controller Fang Yongsheng. This follows a September 21 change where two partnerships shifted their executive partner from Fang to Liang Kecheng, reducing Fang's voting rights from 32.24% to 28.43%. Fang has objected. Additionally, a lawsuit seeks to dissolve the controlling shareholder itself, which could alter control.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- All agree that the core business of Shuo Shi Bio is losing money in 2026 despite a pandemic windfall, which is a fundamental problem.
- Everyone recognizes that the unanimous action pact broke down in July 2025, triggering the current power struggle.
- All participants acknowledge that the dispute is playing out through legal channels in China's court system.
- There is agreement that the company's pandemic-era profits masked underlying weaknesses in its business model.
Points of contention
- The Eastern Agent sees this as a clash between Chinese governance culture and Western litigation, while the Neutral and Regional Agents view it as a structural control failure.
- The Eastern Agent argues the partnership control structure worked well during growth, but the Neutral and Regional Agents say it was always fragile and just masked by profits.
- The Regional Agent frames this as a regulatory blind spot, while the Neutral Agent says it's a deliberate policy choice, not an oversight.
- The Eastern Agent praises the legal system for handling the dispute, but the others point out he also condemns Liang Xilin for using those same courts.
Blind spots
- All participants focus heavily on the power struggle and governance structure, but none deeply analyze why management failed to diversify the business after the pandemic windfall.
- The human cost for employees is mentioned but not explored in detail—no one discusses specific impacts on workers or local communities.
- The geopolitical dimension is raised by the Eastern Agent, but the others don't fully address how Western media narratives might affect investor confidence or regulatory reforms.
- No one examines whether the company's diagnostics business has any long-term competitive advantages or market potential beyond the pandemic.
WorldAttention’s read
The Shuo Shi Bio dispute reveals a company where a fragile control structure, built on partnership agreements rather than direct ownership, collapsed when pandemic profits dried up. While the Eastern Agent defends this as a test of Chinese governance culture that the system is passing, the Neutral and Regional Agents argue it's a governance failure that was always waiting to happen. All sides agree the real issue is that the company burned through its COVID windfall without building a sustainable business, leaving it losing money in 2026. The power struggle over board seats and partnership dissolution is largely a distraction from this fundamental problem. Employees and investors are left bearing the cost of a fight between wealthy partners, while the company's core diagnostics business struggles to survive. The debate shows that whether you see this as a cultural clash, a legal case study, or a regulatory gap, the bottom line is that management failed to turn short-term profits into long-term stability.
Reporting timeline
Shuoshi Bio control dispute escalates as controlling shareholder seeks board election without current chairman
The internal conflict at Shuoshi Bio (SH688399) has intensified after its three actual controllers parted ways in July. On September 24, the company announced that its controlling shareholder, Shaoxing Runkang Bio-Medical Investment Partnership (Runkang Bio), had requested an extraordinary shareholder meeting to elect a new board of directors. The proposed slate of eight candidates includes former controller Fang Yongsheng but excludes current chairman Wang Guoqiang and director Liang Kecheng. This move follows a September 21 announcement that two shareholder partnerships, Taizhou Shuokang and Taizhou Shuoyuan, changed their executive partners from Fang Yongsheng to Liang Kecheng, reducing Fang's controlled voting rights from 32.24% to 28.43%. Fang has disputed this change. Additionally, Runkang Bio itself faces a lawsuit from limited partner Liang Xilin seeking its dissolution, which could further alter control. The company warned that if the court dissolves Runkang Bio, the controlling shareholder and actual controller may change.
Read sourceShuoshi Bio Control Dispute Escalates: Major Shareholder Seeks Board Election, Current Chairman Excluded
The control dispute at Shuoshi Bio (Shuoshi Biotechnology) has intensified. On September 24, the company announced that its controlling shareholder, Shaoxing Runkang Bio-Medical Investment Partnership (Runkang Bio), had requested a temporary shareholder meeting to elect a new board of directors. The proposed slate of eight candidates excludes current Chairman Wang Guoqiang and Director Liang Kecheng. This move follows a September 21 announcement that the executive partners of two shareholder entities, Taizhou Shuokang and Taizhou Shuoyuan, were changed from actual controller Fang Yongsheng to Liang Kecheng, reducing Fang's controlled voting rights from 32.24% to 28.43%. Fang has disputed this change. Additionally, Runkang Bio itself is facing a lawsuit from limited partner Liang Xilin, who is seeking to dissolve the partnership. If the court rules in favor of dissolution, Fang would lose his position as executive partner, potentially leading to a change in the company's controlling shareholder and actual controller. The company warned of significant uncertainty regarding the outcome.
Read sourceDispute over control of Shuo Shi Bio emerges as former partners end pact
A control dispute is unfolding at Chinese diagnostics firm Shuo Shi Bio (硕世生物) after former partners ended their alliance. On September 22, 2026, the company announced that limited partners Taizhou Shuokang and Taizhou Shuoyuan changed their executive partner from actual controller Fang Yongsheng to Liang Kacheng, the grandson of former co-controller Liang Xilin. This followed the July 2026 termination of a long-standing unanimous action pact among Fang, Liang, and Wang Guoqiang, leaving Fang as sole actual controller with a reduced stake of 32.24%. Liang Xilin has filed a lawsuit seeking to dissolve the holding company, which could further change control. The company has posted losses for three consecutive years, with a net loss of 374 million yuan in 2023 and continued losses in 2025. In response, management took voluntary pay cuts in August 2025. The first half of 2026 showed a net profit of 19.56 million yuan, though core operations remained unprofitable. The lawsuit outcome remains uncertain, and the company warns of potential control changes if the holding company is dissolved.
Show 2 older updatesHide older updates
Shuoshi Bio's actual controller loses voting rights as two partnerships change hands
Shuoshi Bio (688399) is undergoing significant control structure changes. Actual controller Fang Yongsheng's disposable voting rights dropped from 32.24% to 28.43% after two partnerships, Taizhou Shuokang and Taizhou Shuoyuan, changed their executive partner from Fang to Liang Kecheng. Fang has objected to the change and may challenge it through litigation. The shift follows the termination of a three-person unanimous action agreement in July, which reduced the controlling group's stake from 40.97% to 32.24%. Additionally, limited partner Liang Xilin has filed a lawsuit seeking dissolution of the holding entity Run Kang Bio, which holds 27.53% of Shuoshi Bio's shares. If the court rules for dissolution, the controlling shareholder and actual controller could change. The board election, originally due September 19, has been postponed as the company continues discussions with shareholders about board composition. The current board includes Chairman and GM Wang Guoqiang, Honorary Chairman Fang Yongsheng, and Director Liang Kecheng.
Read sourceShuoshi Biology's actual controller's voting rights drop as two partnerships change hands
Shuoshi Biology (硕世生物) disclosed on September 21 that two limited partnerships, Taizhou Shuokang and Taizhou Shuoyuan, changed their executive partners from actual controller Fang Yongsheng to Liang Kecheng, reducing Fang's disposable voting rights from 32.24% to 28.43%. Fang has objected to the change and may seek legal action. This follows the termination of a joint action agreement in July that reduced the controlling group from three individuals to Fang alone. Meanwhile, limited partner Liang Xilin has filed a lawsuit to dissolve another partnership, Run Kang Bio, which holds 27.53% of Shuoshi Biology shares. If the court orders dissolution, the company's controlling shareholder and actual controller could change. The company also announced that its board of directors' term expired on September 19 and elections have been postponed due to ongoing shareholder negotiations. The board will continue operating until the election is completed.
Read source